CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
细胞因子装甲 CAR-T 细胞研发进展
英文原题：Progress in the development of cytokine armoured CAR T cells.
查看英文原题
Progress in the development of cytokine armoured CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞工程已从第一代构建体发展至复杂的第四代装甲型 CAR-T 细胞。这些先进细胞经工程化改造，可在表达 CAR 的同时共表达细胞因子、趋化因子或其他免疫调节因子，旨在增强 CAR-T 细胞在肿瘤微环境中的疗效、安全性和持续性。尤其是逆转免疫抑制的潜力，有望使其用于迫切需要新治疗选择的实体瘤。本文综述细胞因子增强型 CAR-T 细胞的临床与临床前研究发现，并讨论通过条件性细胞因子分泌降低全身毒性的策略。
展开英文摘要原文
The engineering of chimeric antigen receptor (CAR) T cells has evolved from first-generation constructs to sophisticated armoured CAR T cells of the fourth generation.
These advanced cellular constructs are engineered to co-express cytokines, chemokines or other immunomodulatory factors alongside CARs, aiming to enhance the efficacy, safety and persistence of CAR T cells within the tumour microenvironment. In particular, the potential for reversion of immunosuppression may allow for the treatment of solid tumours, which are in need of new therapeutic options.
Here, we explore clinical and preclinical findings with cytokine-enhanced CAR T cells and discuss strategies for conditional cytokine secretion to mitigate systemic toxicity.
论文信息
- 作者
- Prasad K、Cross RS、Jenkins MR
- 第一作者单位
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.Australia
- 通讯作者单位
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. Jenkins.m@wehi.edu.au.Australia
- 文献类型
- 综述
- 期刊
- Nature reviews. Immunology2026 Jul
- 原文标识
- PubMed 41792262 · DOI 10.1038/s41577-026-01280-8